Antiphospholipid antibody syndrome (APS) requires long-term anticoagulation to prevent
recurrent thrombosis. Direct oral anticoagulants (DOACs) have been increasingly used in …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Background Antiviral drugs are administered in patients with severe COVID‐19 respiratory
syndrome, including those treated with direct oral anticoagulants (DOACs). Concomitant …

Essentials• Currently, DOACs are given at fixed doses and do not require laboratory
monitoring.• Direct oral anticoagulant‐specific measurements were performed at trough and …

Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring
anticoagulation. With similar or better efficacy and safety outcomes and easier use in the …

Abstract The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) study
prospectively evaluated a prespecified periprocedural-interruption strategy of direct oral …

Background Serious bleeding events have been frequently described in patients taking
direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma …

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

Abstract Background Direct oral anticoagulants (DOACs) do not require concentration
monitoring. However, whether DOAC concentrations are stable and their variation between …